What We Do
Founded in 2006 by Executive Chairman and Founder of Advanced Dermatology Dr. Matt Leavitt, Ameriderm conducts and publishes the results of research studies that advance the practice of dermatology by developing better treatments for patients with dermatologic conditions.
Recently, concerns over the magnitude of COVID-19’s effect on the timely detection and management of melanoma and non-melanoma skin cancers led an elite team of researchers, including Ameriderm’s Director of Research Dr. James Solomon and Dr. Leavitt to participate in research that was published in the Journal of the American Academy of Dermatology (JAAD).
Dr. Solomon and Advanced Dermatology’s Dr. Murray Cotter also participated in a recent study that demonstrated the effectiveness of Total-Body Skin Cancer Exams, which was published in the Journal of Clinical Oncology®, an American Society of Clinical Oncology (ASCO) Journal.
We provide our vast patient population with leading-edge solutions to skin conditions by providing access to new drugs and treatments through pharmaceutical/device company initiated, FDA-supervised clinical trials approved by Institutional Review Boards (IRB).
Our centralized administrative office oversees contracting, provides uniform methodology, assures quality, and provides exemplary data documentation.
The FDA requires that clinical-trial participants are treated with a very high standard of care and that safety is the highest priority. Before the trial, participants can expect to have physical exams, including EKGs and blood work – and they will be monitored very closely throughout the trial by people who report to the FDA. There is a concentration on each participant’s general health. Tests may reveal health issues they are unaware of. Certain underlying health concerns may be a disqualifier for some clinical trials.
We are committed to providing comprehensive and unparalleled dermatologic clinical research in a welcoming and engaging environment.